-
公开(公告)号：US09192617B2
公开(公告)日：2015-11-24
申请号：US13833097
申请日：2013-03-15
IPC分类号： A61K31/7034 , A61K45/06 , A61K31/135 , A61K31/365 , A61K31/7048 , A61K9/20
CPC分类号： A61K31/166 , A61K9/2018 , A61K31/135 , A61K31/18 , A61K31/351 , A61K31/365 , A61K31/7034 , A61K31/7048 , A61K45/06 , H02M1/4225 , H02M7/2176 , H02M2001/4291 , H02P7/29 , Y02B70/126 , A61K2300/00
摘要： The invention relates to the treatment of metabolic disorders in an overweight or obese patient characterized in that empagliflozin and one or more antiobesity drugs are administered to the patient.
摘要翻译： 本发明涉及超重或肥胖患者中代谢紊乱的治疗，其特征在于向患者施用帝格列利嗪和一种或多种抗肥胖药物。
-
公开(公告)号：US20140303097A1
公开(公告)日：2014-10-09
申请号：US14244196
申请日：2014-04-03
申请人： Uli Christian BROEDL , Odd-Erik JOHANSEN , Gabriel Woojai KIM , Eric Williams MAYOUX , Afshin SALSALI , Nima SOLEYMANLOU , Maximilian von EYNATTEN , Hans-Juergen WOERLE , David Z.I. CHERNEY , Bruce A. PERKINS , Andreas DAIBER , Thomas MUENZEL
发明人： Uli Christian BROEDL , Odd-Erik JOHANSEN , Gabriel Woojai KIM , Eric Williams MAYOUX , Afshin SALSALI , Nima SOLEYMANLOU , Maximilian von EYNATTEN , Hans-Juergen WOERLE , David Z.I. CHERNEY , Bruce A. PERKINS , Andreas DAIBER , Thomas MUENZEL
IPC分类号： A61K31/7048 , A61K31/522 , A61K31/155
CPC分类号： A61K31/7048 , A61K9/2018 , A61K9/2866 , A61K31/155 , A61K31/522 , A61K31/7034 , A61K45/06 , A61K2300/00
摘要： The present invention relates to certain SGLT-2 inhibitors for treating and/or preventing oxidative stress, for example in patients with type 1 or type 2 diabetes, as well as to the use of such SGLT-2 inhibitors in treatment and/or prevention of cardiovascular diseases in patients, for example type 1 or type 2 diabetes patients. The present invention further relates to certain SGLT-2 inhibitors for treating and/or preventing a metabolic disorder and preventing, reducing the risk of or delaying the occurrence of a cardiovascular event in patients, for example patients with type 1 or type 2 diabetes.
摘要翻译： 本发明涉及用于治疗和/或预防氧化应激的某些SGLT-2抑制剂，例如在1型或2型糖尿病患者中，以及使用这样的SGLT-2抑制剂治疗和/或预防 患者心血管疾病，例如1型或2型糖尿病患者。 本发明还涉及用于治疗和/或预防代谢紊乱并预防，降低患者，例如1型或2型糖尿病患者心血管事件发生或延缓发生的风险的某些SGLT-2抑制剂。
-
公开(公告)号：US20140315832A1
公开(公告)日：2014-10-23
申请号：US14253935
申请日：2014-04-16
申请人： Uli Christian BROEDL , Odd-Erik JOHANSEN , Eric Williams MAYOUX , Nima SOLEYMANLOU , Maximilian von EYNATTEN , Hans-Juergen WOERLE , David Z.I. CHERNEY , Bruce A. PERKINS
发明人： Uli Christian BROEDL , Odd-Erik JOHANSEN , Eric Williams MAYOUX , Nima SOLEYMANLOU , Maximilian von EYNATTEN , Hans-Juergen WOERLE , David Z.I. CHERNEY , Bruce A. PERKINS
IPC分类号： A61K31/7048 , A61K45/06
摘要： The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.
摘要翻译： 本发明涉及用于治疗，预防，保护和/或延缓患者例如糖尿病前期，1型或2型糖尿病患者的慢性肾脏疾病进展的某些SGLT-2抑制剂。
-
公开(公告)号：US20130252908A1
公开(公告)日：2013-09-26
申请号：US13833097
申请日：2013-03-15
IPC分类号： A61K31/7034 , A61K45/06
CPC分类号： A61K31/166 , A61K9/2018 , A61K31/135 , A61K31/18 , A61K31/351 , A61K31/365 , A61K31/7034 , A61K31/7048 , A61K45/06 , H02M1/4225 , H02M7/2176 , H02M2001/4291 , H02P7/29 , Y02B70/126 , A61K2300/00
摘要： The invention relates to the treatment of metabolic disorders in an overweight or obese patient characterized in that empagliflozin and one or more antiobesity drugs are administered to the patient.
摘要翻译： 本发明涉及超重或肥胖患者中代谢紊乱的治疗，其特征在于向患者施用帝格列利嗪和一种或多种抗肥胖药物。
-
公开(公告)号：US20130137646A1
公开(公告)日：2013-05-30
申请号：US13484506
申请日：2012-05-31
IPC分类号： A61K31/7048 , A61K31/7034 , A61K45/06 , C07H7/04
CPC分类号： A61K31/5513 , A61K31/351 , A61K31/381 , A61K31/4515 , A61K31/551 , A61K31/7034 , A61K31/7048 , A61K45/06 , C07H7/04 , A61K2300/00
摘要： The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an SGLT2 inhibitor.
摘要翻译： 本发明涉及通过用精神抑制剂治疗来预防，减缓患者诱导的代谢紊乱的进展，延缓或治疗的方法，包括向患者施用SGLT2抑制剂。
-
-
-
-
搜索结果
5 条记录 (耗时 0.022 秒)
